Everest Medicines (HKSE:01952) Total Payout Yield % : -0.52 (As of Jun. 24, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Everest Medicines's current Total Payout Yield % is -0.52%.

Everest Medicines Total Payout Yield % Historical Data

The historical data trend for Everest Medicines's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Total Payout Yield % Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Yield %

Get a 7-Day Free Trial

-20.24

0.66

-0.11

-0.49

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Payout Yield %	Get a 7-Day Free Trial					-0.07	-0.05	-0.16	-0.50	-0.42

Competitive Comparison of Everest Medicines's Total Payout Yield %

For the Biotechnology subindustry, Everest Medicines's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Total Payout Yield % falls into.

Everest Medicines Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Everest Medicines's Total Payout Yield % for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	32.58	+	0)	/	6674.5404
	=	-0.49%

Everest Medicines's annualized Total Payout Yield % for the quarter that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	14.024	+	0)	*	2	/	6674.5404
	=	-0.42%

Everest Medicines Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Everest Medicines Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines (HKSE:01952) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Ra Capital Management, L.p.	2102 Investment manager
Kolchinsky Peter	2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Fu Wei	2307 Founder of a discretionary trust who can infl
Janchor Partners Limited	2102 Investment manager
C-bridge Capital Gp, Ltd.	2501 Other
Vistra Trust (singapore) Pte. Limited	2501 Other
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited	2101 Beneficial owner

Everest Medicines (HKSE:01952) Headlines

No Headlines